Abstract:Xiaoning Li, 1 Shuhong Yang, 1 Liang Wang, 1 Peng Liu, 1 Shuang Zhao, 1 Huizhou Li, 1 Yuqing Jiang, 2 Yuexian Guo, 2 Xiuli Wang 1 1 Department of Anesthesiology, The Third Hospital of Hebei Medical University, Qiaoxi District, Shijiazhuang 050051, China; 2 Department of Urology, The Third Hospital of Hebei Medical University, Qiaoxi District, Shijiazhuang 050051, China Background: Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) is one of the essential signaling pathways for the development and maintenance of neuropathic pain. Objective: To investigate the effect of resveratrol (RES) on paclitaxel-induced neuropathic pain in rats and elucidate the underlying molecular mechanisms. Method: Male Sprague Dawley rats were randomly divided into seven groups (n=10/group): Group C, Group P, Group R, Group R+P, Group LY + R+P, Group LY (the specific inhibitor of PI3K), Group E (the specific inhibitor of sirtuin 1 [Sirt1]). Paw withdrawal mechanical threshold (PWT) and thermal withdrawal latency (TWL) were recorded. Mitochondrial histomorphology was performed by transmission electron microscope. PI3K, p-Akt, and t-Akt expressions were tested using immunohistochemistry. Western blot was used to detect p-Akt, t-Akt, SIRT1, and PGC1α expressions. The apoptosis in the striatum, spinal dorsal horns (SDH), and dorsal root ganglions (DRG) tissues was assayed by TUNEL. ELISA was used to detect the contents of IL-β, IL-10, malondialdehyde (MDA), and superoxide dismutase (SOD) in striatum, SDH, and DRG tissues. Results: Compared to the control group, PWT and TWL in the P and LY +R+P groups were significantly decreased on 8th and 14th day after paclitaxel administration ( P <0.05). The expressions of p-Akt, SIRT1, and PGC1α were decreased in paclitaxel-induced neuropathic rats; however, the expressions of p-Akt, SIRT1, and PGC1α were significantly increased after RES treatment ( P <0.05). Furthermore, the expression of p-Akt was decreased by LY294002 ( P <0.05), and amount of SIRT1 and PGC1α expression was inhibited by EX-527 ( P <0.05). The t-Akt level was not significantly changed in all groups. RES prevented paclitaxel-induced mitochondrial damage by PI3K/Akt. RES improves the pain symptoms of paclitaxel neuralgia rats by increasing the IL-10 and decreasing the expression of IL-1β. RES increases the SOD and reduces the MDA. RES reduces apoptosis by SIRT1/PGC1α signal pathway. Conclusion: Our results suggest that RES may inhibit paclitaxel-induced neuropathic pain via PI3K/Akt and SIRT1/PGC1α pathways. Keywords: resveratrol, paclitaxel, neuropathic pain, PI3K/Akt, SIRT1/PGC1α

Duloxetine Attenuates Paclitaxel-Induced Peripheral Nerve Injury by Inhibiting p53-Related Pathways

Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial)

Ursolic acid alleviates paclitaxel-induced peripheral neuropathy through PPARγ activation

Quercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKCε-dependent activation of TRPV1

Blockade of CCR5 suppresses paclitaxel-induced peripheral neuropathic pain caused by increased deoxycholic acid

CX3CL1-mediated Macrophage Activation Contributed to Paclitaxel-Induced DRG Neuronal Apoptosis and Painful Peripheral Neuropathy

Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy

Desloratadine ameliorates paclitaxel-induced peripheral neuropathy and hypersensitivity reactions in mice

Advances in Peripheral Neuropathy Induced by Chemotherapy and Its Prevention and Treatment

Inhibition of Notch pathway Alleviates nab-Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing HMGB1/TLR4 Signaling in Spinal Cord

Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1α pathway

Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer

Puerarin suppresses TRPV1, calcitonin gene-related peptide and substance P to prevent paclitaxel-induced peripheral neuropathic pain in rats

Paclitaxel Inhibits KCNQ Channels in Primary Sensory Neurons to Initiate the Development of Painful Peripheral Neuropathy

Schwann Cell-Derived Exosomes Ameliorate Paclitaxel-Induced Peripheral Neuropathy Through the miR-21-Mediated PTEN Signaling Pathway

Up-regulation of CX3CL1 Via Nuclear Factor-κB–dependent Histone Acetylation is Involved in Paclitaxel-induced Peripheral Neuropathy

Puerarin Relieves Paclitaxel-Induced Neuropathic Pain: the Role of Nav1.8 Β1 Subunit of Sensory Neurons

Attenuation of p38 MAPK/NF‐κB/TRPV1/CGRP is involved in the antinociceptive effect of hesperidin methyl chalcone and taxifolin in paclitaxel‐induced peripheral neuropathy

Daidzein attenuated paclitaxel-induced neuropathic pain via the down-regulation of TRPV1/P2Y and up-regulation of Nrf2/HO-1 signaling

Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation

DNA damage induced PARP-1 overactivation confers paclitaxel-induced neuropathic pain by regulating mitochondrial oxidative metabolism